An investigational dual GCGR/GLP-1R agonist studied in obesity and metabolic liver-disease clinical research programs.
Pre-loaded with a typical Survodutide vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Survodutide. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 600 mcg – 4.8 mg | once weekly | subcutaneous | Phase 2 obesity dose-finding trial (once-weekly subcutaneous survodutide) le Roux et al. evaluated approximately 0.6-4.8 mg once weekly over 46 weeks in adults with obesity. These are clinical-trial exposures for the investigational product, not RUO use instructions. |
| 600 mcg – 2.4 mg | once weekly after escalation | subcutaneous | Lower titration band within the same development literature Trial designs generally escalate gradually because gastrointestinal tolerability is exposure-related for this class. |
People searching this page also look for: survodutide peptide dosage.
Survodutide (BI 456906) is an investigational peptide agonist designed to activate both the glucagon receptor and the GLP-1 receptor. The dual-agonist rationale combines GLP-1-linked appetite and glycemic effects with glucagon-linked energy-expenditure and hepatic-metabolism effects. Peer-reviewed Phase 2 work in adults with obesity reported dose-dependent body-weight reductions over multi-month once-weekly subcutaneous regimens, and additional studies have examined cirrhosis pharmacokinetics and broader cardiometabolic markers.
This compound is advancing through sponsored clinical development programs (including SYNCHRONIZE trial designs). That clinical-development context is not the same thing as research-grade bulk peptide sold for laboratory use.
Critical compliance note: research-grade survodutide is Research Use Only. It is not an FDA-approved drug product, not a finished clinical-trial medication kit for consumer use, and not for human consumption. Any mg-range figures below summarize published trial literature for education only.
Survodutide co-activates the glucagon receptor (GCGR) and GLP-1 receptor. GLP-1 receptor engagement supports satiety signaling, delayed gastric emptying, and glucose-dependent insulinotropic effects. Glucagon receptor engagement is studied for increases in energy expenditure, fat oxidation, and hepatic lipid handling. The dual profile is intended to differentiate from GLP-1 monoagonists in weight-loss magnitude and liver-fat biology, which is why MASLD/MASH endpoints appear in the development program.
obesity and energy-balance pharmacology · dual incretin/glucagon agonist design · MASLD/MASH metabolic liver research · glycemic and cardiometabolic biomarkers · once-weekly peptide PK/PD
Obesity-medicine researchers, hepatology groups focused on metabolic liver disease, and incretin-pharmacology labs are the primary audience. Comparative work against GLP-1 monoagonists and other dual/triple agonists is a major theme.
Lyophilized research material should be kept cold, dry, and dark. Reconstituted solutions belong in refrigerated storage with aliquotting to limit freeze-thaw, following the laboratory SOP.
In research practice, survodutide is usually compared with semaglutide, tirzepatide, or other next-generation agonists rather than stacked with them. Combination experimental arms, when used, are designed to dissect receptor contributions, not to create consumer stacks.
The questions people actually search for, answered plainly.
Published Phase 2 obesity research evaluated roughly 0.6 mg to 4.8 mg once weekly subcutaneously. That describes investigational clinical-trial product exposures, not research-grade RUO instructions.
As an investigational dual agonist it has been studied in clinical trials, but research-grade material is RUO and not an approved finished drug product for consumer or clinical substitution use.
Semaglutide is a GLP-1 receptor monoagonist. Survodutide is designed to activate both glucagon and GLP-1 receptors, adding glucagon-pathway metabolic effects to incretin biology.
Dual GCGR/GLP-1R pharmacology is being studied for effects on liver fat and related metabolic-liver endpoints in addition to body weight.
No. Sponsored clinical-trial drug product and bulk laboratory RUO peptide are different supply and regulatory categories. RUO material is not for human consumption.
As with other incretin-based agonists, gastrointestinal adverse events are a prominent class-level theme and influence dose-escalation design.
Long-acting designs usually involve careful concentration verification, stable reconstitution practices, and PK sampling schedules matched to multi-day exposure.
Primary literature on Survodutide. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides